High rates of multidrug-resistant and rifampicin-resistant tuberculosis among re-treatment cases: where do they come from?

Abstract

BackgroundGlobally 3.9% of new and 21% of re-treatment tuberculosis (TB) cases are multidrug-resistant or rifampicin-resistant (MDR/RR), which is often interpreted as evidence that drug resistance results mainly from poor treatment adherence. This study aims to assess the respective contributions of the different causal pathways leading to MDR/RR-TB at re-treatment.MethodsWe use a simple mathematical model to simulate progression between the different stages of disease and treatment for patients diagnosed with TB. The model is parameterised using region and country-specific TB disease burden data reported by the World Health Organization (WHO). The contributions of four separate causal pathways to MDR/RR-TB among re-treatment cases are estimated: I) initial drug-susceptible TB with resistance amplification during treatment; II) initial MDR/RR-TB inappropriately treated as drug-susceptible TB; III) MDR/RR-TB relapse despite appropriate treatment; and IV) re-infection with MDR/RR-TB.ResultsAt the global level, Pathways I, II, III and IV contribute 38% (28–49, 95% Simulation Interval), 44% (36–52, 95% SI), 6% (5–7, 95% SI) and 12% (7–19, 95% SI) respectively to the burden of MDR/RR-TB among re–treatment cases. Pathway II is dominant in the Western Pacific (74%; 67–80 95% SI), Eastern Mediterranean (68%; 60–74 95% SI) and European (53%; 48–59 95% SI) regions, while Pathway I makes the greatest contribution in the American (53%; 40–66 95% SI), African (43%; 28–61 95% SI) and South-East Asian (50%; 40–59 95% SI) regions.ConclusionsGlobally, failure to diagnose MDR/RR-TB at first presentation is the leading cause of the high proportion of MDR/RR-TB among re-treatment cases. These findings highlight the need for contextualised solutions to limit the impact and spread of MDR/RR-TB.Electronic supplementary materialThe online version of this article (doi:10.1186/s12879-016-2171-1) contains supplementary material, which is available to authorized users.

Risk factors for multidrug‐resistant tuberculosis in northwest Ethiopia: A case–control study

“…Acquired MDR‐TB, the most common type of MDR‐TB in many settings, occurs as a result of sub‐optimal first‐line TB treatment, which is often related to health system or patient factors (Faustini, Hall, & Perucci, ; Han et al, ). There is increasing evidence that primary MDR‐TB is common and that many patients with MDR‐TB had it from the start of treatment, highlighting the need for universal drug susceptibility testing (Dheda et al (); Ragonnet, Trauer, Denholm, Marais, & McBryde, ; Shah et al, ).…”

Mycobacterium tuberculosis Drug Resistance and Transmission among Human Immunodeficiency Virus–Infected Patients in Ho Chi Minh City, Vietnam

“…5 However, it has been demonstrated that many retreatment cases with MDR-TB also represent transmitted drug resistance. 6 The epidemic spread of MDR-TB is a particular concern in areas with poor control of ongoing TB transmission, especially among HIV-infected patients with severe immunodeficiency where health-care facilities can serve as epidemic amplifiers. 7,8 Global TB control efforts have been complicated by increased drug resistance and the negative synergism of TB and HIV coinfection.…”

Treatment adherence among sputum smear-positive pulmonary tuberculosis patients in Xinjiang, China: a prospective study

“…In recent years, there has been a high incidence of new cases of TB worldwide because of the increased population, the oating population, the increased incidence of drug-resistant TB, latent infection, and the AIDS epidemic. 28,29 In 2015, the WHO proposed a moratorium on TB that aimed to reduce the incidence of TB by 90% by 2035. 30 At present, there is no early diagnostic procedure for TB, leading to delayed treatment in most TB patients.…”